Article Link: FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma CAMBRIDGE, Mass. and BEIJING, China, Nov. 14...
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
Article Link: FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell...
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
Article Link: FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis divisi...
FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults
Article Link: FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults T...
FDA Approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for Adults 65 Years of Age and Older
Article Link: FDA Approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for Adults 65 Years of Age and Older PARIS, Nov. 4, 2019 /P...
FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis
Article Link: FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOB...
FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prevent Pregnancy for up to Six Years
Article Link: FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prevent Pregnancy for up to Six Years SAN FRANCISCO ...
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
Article Link: FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy...
FDA Approves Baxdela (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Article Link: FDA Approves Baxdela (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) MORRISTOWN, N.J., Oc...
FDA Approves Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
Article Link: FDA Approves Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer 2...
